ArticleCancer medicine2021
Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A new prediction model for overall survival of elderly patients with solitary bone plasmacytoma: A population-based study.Frontiers in public health · 2022Trial
- Solitary Pancreatic Extramedullary Plasmacytoma Diagnosed Through Endoscopic Ultrasound-Guided Fine-Needle Biopsy-The Role of Endoscopic Diagnosis and Multidisciplinary Approach: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Giant Ulcerative Solitary Plasmacytoma of the Sternum: Resection with Reconstruction in a Resource-Limited Setting.Annals of thoracic surgery short reports · 2025Article
- Article
- Intradural extramedullary solitary plasmacytoma originating in the cervical spine in the setting of refractory multiple myeloma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Sternal Tumor Resection and Complex Chest Wall Reconstruction of a Solitary Plasmacytoma: A Report of a Rare Case.Cureus · 2025Article
- Solitary Plasmacytomas: Current Status in 2025.Hematology reports · 2025Review
- Association between radiotherapy and overall survival or cancer-specific survival in patients with solitary plasmacytoma of bone at pre-B cell grade: a real-world study using the SEER database.Annals of hematology · 2025Article
- Clinical characteristics and prognostic factors of patients with solitary plasmacytoma: a multicenter retrospective study.Therapeutic advances in hematology · 2025Article
- Imaging of Multiple Myeloma: Present and Future.Journal of clinical medicine · 2024Review
- Combined endoscopic transorbital and transnasal approach for the management of a solitary plasmacytoma of the sphenoid bone: A case report and literature review.Surgical neurology international · 2024Article
- Article
- Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study.Frontiers in oncology · 2022Article
- Prediction of Solitary Plasmacytoma of Bone in Elderly Patients: A Nomogram and a Risk Classification System for Overall Survival.BioMed research international · 2022Article
- Pathological axis fracture secondary to a solitary bone plasmacytoma: Two cases and a literature review.Surgical neurology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solitary plasmacytoma of bone (SPB) is a single, isolated plasmacytoma originated from the bone. The survival trends of patients with SPB in recent years remain unknown. And the prognostic system of SPB may also need to be refined. The 18 Surveillance, Epidemiology, and End Results (SEER) databases of the National Cancer Institute in the United States were used to extract data for this study. The third edition of the International Classification of Disease for Oncology (ICD-O-3) code 9731 was used to identify cases of SPB. For each case, factors including age at the time of diagnosis, sex, race, marital status, insurance status, primary sites of tumors, and the use of surgery were collected. The outcomes of patients with SPB were compared between two groups. And the prognostic impacts of baseline characteristics and use of surgery was studied. A total of 4103 (from 1976 to 2016) cases of SPB were identified. The median age was 65 years old. Patients in time period-2 (2008-2016) show better survival as compared to those in time period-1(1976-2007) (median overall survival: 88 months vs. 73 months, p = 0.0332). Age ≤ 65 years and being male were associated with better outcomes. The widowed individuals had significantly inferior survival and myeloma-specific survival than the single, married, or divorced individuals (p values all <0.0001). Patients with lesions in bones of skull and face and associated joints had longer survival as compared with those with bone lesions in other sites (median overall survival: 107 months vs. 79 months, p = 0.0694). The use of surgery was significantly associated with improved survival (median survival: surgery performed 98 months vs. not performed 73 months, hazards ratio [HR]: 0.7623, 95% CI: 0.7009-0.8472; p < 0.0001) and myeloma-specific survival (median myeloma-specific survival: surgery 160.0 months vs. no surgery 143.0 months, HR: 0.8469, 95% CI: 0.7493-0.9572; p = 0.0078). Multivariable analysis revealed that surgery, marital status, and age were independent prognostic factors for overall survival in patients with SPB. The improvement in the survival of patients with SPB has been observed in recent years. And several potential prognostic factors were identified. Future prospective studies are warranted to explore the roles of novel agents, surgery, and systemic chemotherapy in the treatment of SPB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.